Crispr Therapeutics remains a Buy with strong pipeline and cash despite slow Casgevy uptake.

Crispr Therapeutics AG is rated a Buy due to its strong drug pipeline, careful capital management, and partnership with Vertex, despite slow adoption of its Casgevy therapy. Casgevy's market growth is limited by harsh preconditioning requirements, but future in vivo treatments and gentler regimens could expand its market significantly. The company has a diversified pipeline including cardiovascular, diabetes, and CAR-T therapies, with important clinical results expected through 2026. With $1.65 billion in net cash and disciplined R&D spending, Crispr has a 5-6 year financial runway, reducing near-term dilution or capital risk for investors.